Why This Biotech Stock Just Doubled In A Single Day Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday? Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Why Is Cidara Therapeutics Stock Trading Higher On Monday? Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3.
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results.
Analysts Can't Get Enough of These Little-Known Biopharma Stocks Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older.
American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance The American Pharmacists Association announced Monday it will withhold endorsement of the CDC's updated immunization schedule.
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr. A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.
RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health experts call a dichotomy in his approach to healthcare policy.
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026.
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.
